Vera Therapeutics

Opinion · Devil's advocate

Fact-check-o-meter

Strong ORIGIN 3 numbers, but the claims run ahead of the public record

Vera's releases and 10-Q agree on cash, losses and the accelerated-approval status. The gaps are in the science: the registry shows only a proteinuria primary outcome while the release says all prespecified endpoints were met, and 'prevented progression' rests on topline counts with no event definitions yet. No litigation is disclosed.

1. Science · weight medium

   'Met all prespecified endpoints' versus a registry that lists only proteinuria

   The company said: "TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial" source

   The record says: The ClinicalTrials.gov record for ORIGIN 3 (last updated Oct. 1, 2026) lists one primary outcome, "Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR)" at 36 weeks, and no eGFR outcome. A June 2 8-K says Vera "aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan". source

   Our view: The eGFR analysis was agreed with the FDA, and the results are large. But the registry does not show the eGFR endpoints or the revised timing, so outsiders cannot check what was prespecified or when. The statistical analysis plan would answer it.

2. Science · weight medium

   A topline release, not the full dataset, carries the 'prevented progression' claim

   The company said: "TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy" source

   The record says: The same release says "Detailed results from the final efficacy analysis will be shared at an upcoming scientific congress" and gives composite kidney progression events as 11 on TRUTAKNA versus 38 on placebo without defining the composite. Its indication box says: "It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN." source

   Our view: An eGFR difference of 5.6 mL/min/1.73m2 at 52 weeks and 11 versus 38 events are strong numbers. 'Prevented' is still a headline word for a topline release that has no event definitions, and the label language about long-term benefit has not changed.

3. Press release vs filing · weight low

   Launch momentum is measured in start forms, and the 10-Q reports no revenue

   The company said: "Strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks." source

   The record says: The Q2 results release says "For the quarter ended June 30, 2026, Vera Therapeutics reported a net loss of $109.5 million" and, for the half year, "net cash used in operating activities was $206.8 million". The 10-Q does not report the start-form figure. source

   Our view: The approval came July 7, so no revenue by June 30 is expected. Start forms are a leading indicator, not patients on therapy or sales. The 10-Q says the company expects limited revenue from product sales in the third quarter of 2026.

4. Press release vs filing · weight low

   $425 million of debt capacity is conditional; the 10-Q expects to raise more capital

   The company said: "plus up to $425 million available under its debt facility, subject to the satisfaction of certain conditions" source

   The record says: The 10-Q says cash "will be sufficient to fund its planned operations and capital expenditure requirements for at least the next 12 months" and that "The Company intends to raise additional capital through public or private equity offerings, debt financing, or other capital sources". Cash was $499.2 million at June 30, down from $714.6 million at Dec. 31, 2025. source

   Our view: The release states the conditions on the debt, which is fair. The $499.2 million compares with a half-year operating cash burn of $206.8 million, and the filing says the company intends to raise additional capital.

5. Legal and disclosure record · weight low

   No securities litigation or enforcement disclosed in the latest filing

   The record says: The Q2 10-Q's legal proceedings section says: "We are not currently a party to any material legal proceedings." source

   Our view: No class action, derivative suit, warning letter or enforcement matter is disclosed. Risk factors on litigation are generic.

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our right of reply.